Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.80 |
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.64 |
| ▸ | CDK4 | P11802 | 5/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.61 |
| ▸ | CCND1 | P24385 | 5/20 | 0.61 |
| ▸ | CDK2 | P24941 | 5/20 | 0.61 |
| ▸ | CCND3 | P30281 | 5/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | JAK1 | P23458 | 2/20 | 0.61 |
| ▸ | TYK2 | P29597 | 2/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | ITK | Q08881 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224535 | 0.90 | FLT3 (0.66) | CHEK1CDK1KDRFGFR1FLT1 | |
| SCHEMBL30801248 | 0.90 | ITK (0.69) | CHEK1CDK1KDRFGFR1FLT1 | |
| SCHEMBL3542400 | 0.90 | ITK (0.69) | CHEK1CDK1KDRFGFR1FLT1 | |
| SCHEMBL5252544 | 0.89 | CHEK1 (1.00) | CHEK1CDK1KDRFGFR1FLT1 | |
| SCHEMBL4919171 | 0.88 | FGFR1 (0.64) | CHEK1CDK1KDRFGFR1FLT1 | |
| SCHEMBL5951804 | 0.86 | CHEK1 (0.86) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5952926 | 0.86 | CHEK1 (0.73) | CHEK1CDK1KDRFGFR1FLT1 | |
| SCHEMBL5253261 | 0.84 | CHEK1 (1.00) | CHEK1CDK1KDRFGFR1FLT1 | |
| SCHEMBL5952883 | 0.84 | MAP2K4 (0.60) | CHEK1CDK1KDRPDPK1 | |
| SCHEMBL5952795 | 0.84 | MAP2K4 (0.60) | CHEK1CDK1KDRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1614683-B1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMA (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1218348-B1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2007-10-24 | — | — | EP | disclosed |
| US-7141587-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | CHEK1 286/4885CDK1 36/4885KDR 2231/4885 |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | CHEK1 320/4885CDK1 23/4885KDR 60/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | CHEK1 321/4885CDK1 5/4885KDR 2609/4885 |
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | CHEK1 798/4885CDK1 820/4885KDR 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.